Imprint of parity and age at first pregnancy on the genomic landscape of subsequent breast cancer.

Abstract:

BACKGROUND:Although parity and age at first pregnancy are among the most known extrinsic factors that modulate breast cancer risk, their impact on the biology of subsequent breast cancer has never been explored in depth. Recent data suggest that pregnancy-induced tumor protection is different according to breast cancer subtypes, with parity and young age at first pregnancy being associated with a marked reduction in the risk of developing luminal subtype but not triple negative breast cancer. In this study, we investigated the imprint of parity and age at first pregnancy on the pattern of somatic mutations, somatic copy number alterations, transcriptomic profiles, and tumor immune microenvironment by assessing tumor-infiltrating lymphocytes (TILs) levels of subsequent breast cancer. METHODS:A total of 313 patients with primary breast cancer with available whole genome, RNA sequencing, and TILs data were included in this study. We used a multivariate analysis adjusted for age at diagnosis, pathological stage, molecular subtypes, and histological subtypes. We compared nulliparous vs. parous, late parous vs. early parous, and nulliparous vs. pregnancy-associated breast cancer (PABC) patients. Late and early parous patients were grouped by using the median age at first pregnancy. PABC was defined as patients diagnosed up to 10 years postpartum. RESULTS:Genomic alterations of breast cancer were associated with age at first pregnancy but not with parity status alone. Independently of clinicopathological features, early parous patients developed tumors characterized by a higher number of Indels (Padj = 0.002), a lower frequency of CDH1 mutations (1.2% vs. 12.7%; Padj = 0.013), a higher frequency of TP53 mutations (50% vs. 22.5%; Padj = 0.010), and MYC amplification (28% vs. 7%; Padj = 0.008). PABC were associated with increased TILs infiltration (Padj = 0.0495). CONCLUSIONS:These findings highlight an unprecedented link between reproductive history and the genomic landscape of subsequent breast cancer. We further hypothesize that TP53-mutant premalignant lesions could be less susceptible to the protective effect of an early parity, which might explain the difference of parity-induced protection according to breast cancer subtypes. This work also advocates that reproductive history should be routinely collected in future large-scale genomic studies addressing the biology of female cancers.

journal_name

Breast Cancer Res

authors

Nguyen B,Venet D,Lambertini M,Desmedt C,Salgado R,Horlings HM,Rothé F,Sotiriou C

doi

10.1186/s13058-019-1111-6

subject

Has Abstract

pub_date

2019-02-15 00:00:00

pages

25

issue

1

eissn

1465-5411

issn

1465-542X

pii

10.1186/s13058-019-1111-6

journal_volume

21

pub_type

杂志文章
  • Nongenomic oestrogen signalling in oestrogen receptor negative breast cancer cells: a role for the angiotensin II receptor AT1.

    abstract:INTRODUCTION:Oestrogens can mediate some of their cell survival properties through a nongenomic mechanism that involves the mitogen-activated protein kinase (MAPK) pathway. The mechanism of this rapid signalling and its dependence on a membrane bound oestrogen receptor (ER), however, remains controversial. The role of ...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/bcr1509

    authors: Lim KT,Cosgrave N,Hill AD,Young LS

    更新日期:2006-01-01 00:00:00

  • Antitumor activity of Z-endoxifen in aromatase inhibitor-sensitive and aromatase inhibitor-resistant estrogen receptor-positive breast cancer.

    abstract:BACKGROUND:The tamoxifen metabolite, Z-endoxifen, demonstrated promising antitumor activity in endocrine-resistant estrogen receptor-positive (ER+) breast cancer. We compared the antitumor activity of Z-endoxifen with tamoxifen and letrozole in the letrozole-sensitive MCF7 aromatase expressing model (MCF7AC1), as well ...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/s13058-020-01286-7

    authors: Jayaraman S,Hou X,Kuffel MJ,Suman VJ,Hoskin TL,Reinicke KE,Monroe DG,Kalari KR,Tang X,Zeldenrust MA,Cheng J,Bruinsma ES,Buhrow SA,McGovern RM,Safgren SL,Walden CA,Carter JM,Reid JM,Ingle JN,Ames MM,Hawse JR,Goet

    更新日期:2020-05-19 00:00:00

  • Cytogenetic analysis of HER1/EGFR, HER2, HER3 and HER4 in 278 breast cancer patients.

    abstract:INTRODUCTION:The HER (human EGFR related) family of receptor tyrosine kinases (HER1/EGFR (epidermal growth factor receptor)/c-erbB1, HER2/c-erbB2, HER3/c-erbB3 and HER4/c-erbB4) shares a high degree of structural and functional homology. It constitutes a complex network, coupling various extracellular ligands to intrac...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/bcr1843

    authors: Sassen A,Rochon J,Wild P,Hartmann A,Hofstaedter F,Schwarz S,Brockhoff G

    更新日期:2008-01-01 00:00:00

  • LincIN, a novel NF90-binding long non-coding RNA, is overexpressed in advanced breast tumors and involved in metastasis.

    abstract:BACKGROUND:Recent genome-wide profiling by sequencing and distinctive chromatin signatures has identified thousands of long non-coding RNA (lncRNA) species (>200 nt). LncRNAs have emerged as important regulators of gene expression, involving in both developmental and pathological processes. While altered expression of ...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/s13058-017-0853-2

    authors: Jiang Z,Slater CM,Zhou Y,Devarajan K,Ruth KJ,Li Y,Cai KQ,Daly M,Chen X

    更新日期:2017-05-30 00:00:00

  • ELF5 isoform expression is tissue-specific and significantly altered in cancer.

    abstract:BACKGROUND:E74-like factor 5 (ELF5) is an epithelial-specific member of the E26 transforming sequence (ETS) transcription factor family and a critical regulator of cell fate in the placenta, pulmonary bronchi, and milk-producing alveoli of the mammary gland. ELF5 also plays key roles in malignancy, particularly in basa...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/s13058-015-0666-0

    authors: Piggin CL,Roden DL,Gallego-Ortega D,Lee HJ,Oakes SR,Ormandy CJ

    更新日期:2016-01-07 00:00:00

  • The diagnosis and management of pre-invasive breast disease: promise of new technologies in understanding pre-invasive breast lesions.

    abstract::Array-based comparative genomic hybridization, RNA expression profiling, and proteomic analyses are new molecular technologies used to study breast cancer. Invasive breast cancers were originally evaluated because they provided ample quantities of DNA, RNA, and protein. The application of these technologies to pre-inv...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章,评审

    doi:10.1186/bcr655

    authors: Jeffrey SS,Pollack JR

    更新日期:2003-01-01 00:00:00

  • Targeted therapies in breast cancer: are heart and vessels also being targeted?

    abstract::The concept of 'targeted' therapies implies that such drugs only act on cells that specifically express the particular target, therefore giving rise to a low incidence of side effects. However, targeted therapies currently approved for the treatment of breast cancer have demonstrated a relatively high incidence of car...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章,评审

    doi:10.1186/bcr3142

    authors: Criscitiello C,Metzger-Filho O,Saini KS,de Castro G Jr,Diaz M,La Gerche A,de Azambuja E,Piccart-Gebhart MJ

    更新日期:2012-06-19 00:00:00

  • Vitamin D and breast cancer: interpreting current evidence.

    abstract::Preclinical investigations and selected clinical observational studies support an association between higher vitamin D intake and 25-hydroxyvitamin D levels with lower breast cancer risk. However, the recently updated report from the Institute of Medicine concluded that, for cancer and vitamin D, the evidence was 'inc...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章,评审

    doi:10.1186/bcr2846

    authors: Chlebowski RT

    更新日期:2011-08-16 00:00:00

  • Role of ADAM17 in the non-cell autonomous effects of oncogene-induced senescence.

    abstract:INTRODUCTION:Cellular senescence is a terminal cell proliferation arrest that can be triggered by oncogenes. One of the traits of oncogene-induced senescence (OIS) is the so-called senescence-associated secretory phenotype or senescence secretome. Depending on the context, the non-cell autonomous effects of OIS may var...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/s13058-015-0619-7

    authors: Morancho B,Martínez-Barriocanal Á,Villanueva J,Arribas J

    更新日期:2015-08-12 00:00:00

  • Sulfatide decreases the resistance to stress-induced apoptosis and increases P-selectin-mediated adhesion: a two-edged sword in breast cancer progression.

    abstract:BACKGROUND:We have previously shown that galactosylceramide (GalCer) affects the tumourigenic and metastatic properties of breast cancer cells by acting as an anti-apoptotic molecule. Since GalCer is a precursor molecule in the synthesis of sulfatides, the present study was aimed to define the role of sulfatides in apo...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/s13058-018-1058-z

    authors: Suchanski J,Grzegrzolka J,Owczarek T,Pasikowski P,Piotrowska A,Kocbach B,Nowak A,Dziegiel P,Wojnar A,Ugorski M

    更新日期:2018-11-06 00:00:00

  • Tricho-rhino-phalangeal syndrome 1 protein functions as a scaffold required for ubiquitin-specific protease 4-directed histone deacetylase 2 de-ubiquitination and tumor growth.

    abstract:BACKGROUND:Although numerous studies have reported that tricho-rhino-phalangeal syndrome type I (TRPS1) protein, the only reported atypical GATA transcription factor, is overexpressed in various carcinomas, the underlying mechanism(s) by which it contributes to cancer remain unknown. METHODS:Both overexpression and kn...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/s13058-018-1018-7

    authors: Wang Y,Zhang J,Wu L,Liu W,Wei G,Gong X,Liu Y,Ma Z,Ma F,Thiery JP,Chen L

    更新日期:2018-08-02 00:00:00

  • The estrogen receptor influences microtubule-associated protein tau (MAPT) expression and the selective estrogen receptor inhibitor fulvestrant downregulates MAPT and increases the sensitivity to taxane in breast cancer cells.

    abstract:INTRODUCTION:Microtubule-associated protein tau (MAPT) inhibits the function of taxanes and high expression of MAPT decreases the sensitivity to taxanes. The relationship between estrogen receptor (ER) and MAPT in breast cancer is unclear. In this study, we examined the correlation of MAPT expression with the sensitivi...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/bcr2598

    authors: Ikeda H,Taira N,Hara F,Fujita T,Yamamoto H,Soh J,Toyooka S,Nogami T,Shien T,Doihara H,Miyoshi S

    更新日期:2010-01-01 00:00:00

  • XRCC1 and XPD genetic polymorphisms, smoking and breast cancer risk in a Finnish case-control study.

    abstract:INTRODUCTION:It has been suggested that individuals with reduced DNA repair capacities might have increased susceptibility to environmentally induced cancer. In this study, we evaluated if polymorphisms in DNA repair genes XRCC1 (Arg280His, Arg399Gln) and XPD (Lys751Gln) modify individual breast cancer risk, with empha...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/bcr1333

    authors: Metsola K,Kataja V,Sillanpää P,Siivola P,Heikinheimo L,Eskelinen M,Kosma VM,Uusitupa M,Hirvonen A

    更新日期:2005-01-01 00:00:00

  • Targeted therapy against Bcl-2-related proteins in breast cancer cells.

    abstract:INTRODUCTION:Bcl-2 and Bcl-xL confer resistance to apoptosis, thereby reducing the effectiveness of chemotherapy. We examined the relationship between the expression of Bcl-2 and Bcl-xL and chemosensitivity of breast cancer cells, with the aim of developing specific targeted therapy. METHODS:Four human breast cancer c...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/bcr1323

    authors: Emi M,Kim R,Tanabe K,Uchida Y,Toge T

    更新日期:2005-01-01 00:00:00

  • Rack1 mediates tyrosine phosphorylation of Anxa2 by Src and promotes invasion and metastasis in drug-resistant breast cancer cells.

    abstract:BACKGROUND:Acquirement of resistance is always associated with a highly aggressive phenotype of tumor cells. Recent studies have revealed that Annexin A2 (Anxa2) is a key protein that links drug resistance and cancer metastasis. A high level of Anxa2 in cancer tissues is correlated to a highly aggressive phenotype. Inc...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/s13058-019-1147-7

    authors: Fan Y,Si W,Ji W,Wang Z,Gao Z,Tian R,Song W,Zhang H,Niu R,Zhang F

    更新日期:2019-05-22 00:00:00

  • Dynamic regulation of CD24 and the invasive, CD44posCD24neg phenotype in breast cancer cell lines.

    abstract:INTRODUCTION:The invasive, mesenchymal phenotype of CD44posCD24neg breast cancer cells has made them a promising target for eliminating the metastatic capacity of primary tumors. It has been previously demonstrated that CD44neg/lowCD24pos breast cancer cells lack the ability to give rise to their invasive CD44posCD24ne...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/bcr2449

    authors: Meyer MJ,Fleming JM,Ali MA,Pesesky MW,Ginsburg E,Vonderhaar BK

    更新日期:2009-01-01 00:00:00

  • Fatal attraction: why breast cancer cells home to bone.

    abstract::Osteolytic metastases due to breast cancer are serious events. The interactions between breast cancer cells with the microenvironment of bone have been thought to provide an ideal milieu for cancer cells. Recent data now indicate that migration of breast cancer cells into bone and their subsequent growth into metastas...

    journal_title:Breast cancer research : BCR

    pub_type: 社论

    doi:10.1186/bcr1848

    authors: Hofbauer LC,Rachner T,Singh SK

    更新日期:2008-01-01 00:00:00

  • MiR-7 reduces the BCSC subset by inhibiting XIST to modulate the miR-92b/Slug/ESA axis and inhibit tumor growth.

    abstract:BACKGROUND:Breast cancer stem cells (BCSCs) are typically seed cells of breast tumor that initiate and maintain tumor growth. MiR-7, as a cancer inhibitor, decreases the BCSC subset and inhibits tumor progression through mechanisms that remain unknown. METHODS:We examined miR-7 expression in breast cancer and develope...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/s13058-020-01264-z

    authors: Li M,Pan M,You C,Zhao F,Wu D,Guo M,Xu H,Shi F,Zheng D,Dou J

    更新日期:2020-03-06 00:00:00

  • Not all false positive diagnoses are equal: On the prognostic implications of false-positive diagnoses made in breast MRI versus in mammography / digital tomosynthesis screening.

    abstract:BACKGROUND:Breast magnetic resonance imaging (MRI) has been reported to frequently result in false-positive diagnoses, limiting its positive predictive value (PPV). However, for PPV calculation, all nonmalignant tissue changes are equally considered false-positive, although the respective prognostic importance, and thu...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/s13058-018-0937-7

    authors: Kuhl CK,Keulers A,Strobel K,Schneider H,Gaisa N,Schrading S

    更新日期:2018-02-09 00:00:00

  • Inheritance of deleterious mutations at both BRCA1 and BRCA2 in an international sample of 32,295 women.

    abstract:BACKGROUND:Most BRCA1 or BRCA2 mutation carriers have inherited a single (heterozygous) mutation. Transheterozygotes (TH) who have inherited deleterious mutations in both BRCA1 and BRCA2 are rare, and the consequences of transheterozygosity are poorly understood. METHODS:From 32,295 female BRCA1/2 mutation carriers, w...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章,多中心研究

    doi:10.1186/s13058-016-0768-3

    authors: Rebbeck TR,Friebel TM,Mitra N,Wan F,Chen S,Andrulis IL,Apostolou P,Arnold N,Arun BK,Barrowdale D,Benitez J,Berger R,Berthet P,Borg A,Buys SS,Caldes T,Carter J,Chiquette J,Claes KB,Couch FJ,Cybulski C,Daly MB,d

    更新日期:2016-11-11 00:00:00

  • Treating breast cancer through novel inhibitors of the phosphatidylinositol 3'-kinase pathway.

    abstract::Recent studies indicate that constitutive signaling through the phosphatidylinositol 3'-kinase (PI3K) pathway is a cause of treatment resistance in breast cancer patients. This implies that patients with tumors that exhibit aberrant PI3K signaling may benefit from targeted pathway inhibitors. The first agents to make ...

    journal_title:Breast cancer research : BCR

    pub_type: 评论,杂志文章

    doi:10.1186/bcr1307

    authors: Crowder RJ,Ellis MJ

    更新日期:2005-01-01 00:00:00

  • Epigenetics in breast cancer: what's new?

    abstract::Epigenetic changes are critical for development and progression of cancers, including breast cancer. Significant progress has been made in the basic understanding of how various epigenetic changes such as DNA methylation, histone modification, miRNA expression, and higher order chromatin structure affect gene expressi...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章,评审

    doi:10.1186/bcr2925

    authors: Huang Y,Nayak S,Jankowitz R,Davidson NE,Oesterreich S

    更新日期:2011-01-01 00:00:00

  • Penta-O-galloyl-beta-D-glucose induces G1 arrest and DNA replicative S-phase arrest independently of cyclin-dependent kinase inhibitor 1A, cyclin-dependent kinase inhibitor 1B and P53 in human breast cancer cells and is orally active against triple negati

    abstract:INTRODUCTION:Natural herbal compounds with novel actions different from existing breast cancer (BCa) treatment modalities are attractive for improving therapeutic efficacy and safety. We have recently shown that penta-1,2,3,4,6-O-galloyl-β-D-glucose (PGG) induced S-phase arrest in prostate cancer (PCa) cells through in...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/bcr2634

    authors: Chai Y,Lee HJ,Shaik AA,Nkhata K,Xing C,Zhang J,Jeong SJ,Kim SH,Lu J

    更新日期:2010-01-01 00:00:00

  • Impact of somatic PI3K pathway and ERBB family mutations on pathological complete response (pCR) in HER2-positive breast cancer patients who received neoadjuvant HER2-targeted therapies.

    abstract:BACKGROUND:The Cancer Genome Atlas analysis revealed that somatic EGFR, receptor tyrosine-protein kinase erbB-2 (ERBB2), Erb-B2 receptor tyrosine kinase 3 (ERBB3) and Erb-B2 receptor tyrosine kinase 4 (ERBB4) gene mutations (ERBB family mutations) occur alone or co-occur with somatic mutations in the gene encoding the ...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章,随机对照试验

    doi:10.1186/s13058-017-0883-9

    authors: Toomey S,Eustace AJ,Fay J,Sheehan KM,Carr A,Milewska M,Madden SF,Teiserskiene A,Kay EW,O'Donovan N,Gallagher W,Grogan L,Breathnach O,Walshe J,Kelly C,Moulton B,Kennedy MJ,Gullo G,Hill AD,Power C,Duke D,Hambly N

    更新日期:2017-07-27 00:00:00

  • BRCA1 and BRCA2 mutations in a population-based study of male breast cancer.

    abstract:BACKGROUND:The contribution of BRCA1 and BRCA2 to the incidence of male breast cancer (MBC) in the United Kingdom is not known, and the importance of these genes in the increased risk of female breast cancer associated with a family history of breast cancer in a male first-degree relative is unclear. METHODS:We have c...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/bcr419

    authors: Basham VM,Lipscombe JM,Ward JM,Gayther SA,Ponder BA,Easton DF,Pharoah PD

    更新日期:2002-01-01 00:00:00

  • Increased genomic burden of germline copy number variants is associated with early onset breast cancer: Australian breast cancer family registry.

    abstract:BACKGROUND:Women with breast cancer who have multiple affected relatives are more likely to have inherited genetic risk factors for the disease. All the currently known genetic risk factors for breast cancer account for less than half of the average familial risk. Furthermore, the genetic factor(s) underlying an increa...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/s13058-017-0825-6

    authors: Walker LC,Pearson JF,Wiggins GA,Giles GG,Hopper JL,Southey MC

    更新日期:2017-03-16 00:00:00

  • Additive growth inhibitory effects of ibandronate and antiestrogens in estrogen receptor-positive breast cancer cell lines.

    abstract:INTRODUCTION:Bisphosphonates are inhibitors of osteoclast-mediated tumor-stimulated osteolysis, and they have become standard therapy for the management of bone metastases from breast cancer. These drugs can also directly induce growth inhibition and apoptosis of osteotropic cancer cells, including estrogen receptor-po...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/bcr1363

    authors: Journe F,Chaboteaux C,Magne N,Duvillier H,Laurent G,Body JJ

    更新日期:2006-01-01 00:00:00

  • Immunohistochemical expression of insulin-like growth factor binding protein-3 in invasive breast cancers and ductal carcinoma in situ: implications for clinicopathology and patient outcome.

    abstract:INTRODUCTION:Insulin-like growth factor binding protein-3 (IGFBP-3) differentially modulates breast epithelial cell growth through insulin-like growth factor (IGF)-dependent and IGF-independent pathways and is a direct (IGF-independent) growth inhibitor as well as a mitogen that potentiates EGF (epidermal growth factor...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/bcr963

    authors: Vestey SB,Perks CM,Sen C,Calder CJ,Holly JM,Winters ZE

    更新日期:2005-01-01 00:00:00

  • Prevalence of germline BRCA mutations in HER2-negative metastatic breast cancer: global results from the real-world, observational BREAKOUT study.

    abstract:BACKGROUND:The global observational BREAKOUT study investigated germline BRCA mutation (gBRCAm) prevalence in a population of patients with human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (MBC). METHODS:Eligible patients had initiated first-line cytotoxic chemotherapy for HER2-negativ...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章,多中心研究

    doi:10.1186/s13058-020-01349-9

    authors: O'Shaughnessy J,Brezden-Masley C,Cazzaniga M,Dalvi T,Walker G,Bennett J,Ohsumi S

    更新日期:2020-10-27 00:00:00

  • CRIPTO antagonist ALK4L75A-Fc inhibits breast cancer cell plasticity and adaptation to stress.

    abstract:BACKGROUND:CRIPTO is a multi-functional signaling protein that promotes stemness and oncogenesis. We previously developed a CRIPTO antagonist, ALK4L75A-Fc, and showed that it causes loss of the stem cell phenotype in normal mammary epithelia suggesting it may similarly inhibit CRIPTO-dependent plasticity in breast canc...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/s13058-020-01361-z

    authors: Balcioglu O,Heinz RE,Freeman DW,Gates BL,Hagos BM,Booker E,Mirzaei Mehrabad E,Diesen HT,Bhakta K,Ranganathan S,Kachi M,Leblanc M,Gray PC,Spike BT

    更新日期:2020-11-13 00:00:00